03966nam 2200817Ia 450 991096451450332120240313220347.09780804786577080478657710.1515/9780804786577(CKB)2560000000101867(SSID)ssj0000918466(PQKBManifestationID)11541702(PQKBTitleCode)TC0000918466(PQKBWorkID)10895390(PQKB)10036840(MiAaPQ)EBC1191536(DE-B1597)563694(DE-B1597)9780804786577(Au-PeEL)EBL1191536(CaPaEBR)ebr10704775(OCoLC)846551598(OCoLC)1198930135(PPN)236069934(Perlego)745506(FR-PaCSA)88866724(FRCYB88866724)88866724(EXLCZ)99256000000010186720121026d2013 uy 0engurcn|||||||||txtccrOf medicines and markets intellectual property and human rights in the free trade era /Angelina Snodgrass Godoy1st ed.Stanford, California Stanford University Pressc2013xiv, 183 p. illStanford studies in human rightsBibliographic Level Mode of Issuance: Monograph9780804785600 0804785600 9780804785617 0804785619 Includes bibliographical references and index.Frontmatter -- Contents -- Foreword -- Acronyms and Abbreviations -- Acknowledgments -- 1. Trading Health for Wealth -- 2. A Primer on Pharmaceutical Intellectual Property -- 3. Market Failures and Fallacies -- 4. Local Politics, Strange Bedfellows, and the Challenges of Human Rights Mobilization -- 5. Patient Advocacy and Access to Medicines Litigation -- 6. Writing Globalization’s Rule Book -- Notes -- References -- Index Central American countries have long defined health as a human right. But in recent years regional trade agreements have ushered in aggressive intellectual property reforms, undermining this conception. Questions of IP and health provisions are pivotal to both human rights advocacy and "free" trade policy, and as this book chronicles, complex political battles have developed across the region. Looking at events in Costa Rica, El Salvador, and Guatemala, Angelina Godoy argues that human rights advocates need to approach intellectual property law as more than simply a roster of regulations. IP represents the cutting edge of a global tendency to value all things in market terms: Life forms—from plants to human genetic sequences—are rendered commodities, and substances necessary to sustain life—medicines—are restricted to insure corporate profits. If we argue only over the terms of IP protection without confronting the underlying logic governing our trade agreements, then human rights advocates will lose even when they win.Stanford studies in human rights.Drug accessibilityCentral AmericaDrugsPatentsFree tradeCentral AmericaHuman rightsCentral AmericaIntellectual propertyCentral AmericaPharmaceutical policyCentral AmericaRight to healthCentral AmericaDrug accessibilityDrugsFree tradeHuman rightsIntellectual propertyPharmaceutical policyRight to health338.4/7615109728Godoy Angelina Snodgrass1795356MiAaPQMiAaPQMiAaPQBOOK9910964514503321Of medicines and markets4336533UNINA